KD-414
From Wikipedia, the free encyclopedia
Jump to navigation
Jump to search
Vaccine candidate against COVID-19
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Inactivated |
Clinical data | |
Routes of administration | Intramuscular |
KD-414 is a COVID-19 vaccine candidate developed by KM Biologics Co.[1][2][3]
References[edit]
- ^ "20歳以上65歳未満の健康成人、及び65歳以上の健康な高齢者を対象に、COVID-19に対するワクチン(KD-414)の安全性及び免疫原性を検討するための、プラセボを対照とする多施設共同二重盲検ランダム化並行群間比較試験". jrct.niph.go.jp. Japan Registry of Clinical Trials. Retrieved 7 May 2021.
- ^ "Japan's KM Biologics begins clinical trial of COVID-19 vaccine candidate". Reuters. 22 March 2021.
- ^ "18歳以上の健康な日本人を対象に、COVID-19に対するワクチン(KD-414)を2回接種した際の免疫原性及び安全性を確認する多施設共同非盲検非対照試験。". jrct.niph.go.jp. Japan Registry of Clinical Trials. Retrieved 22 October 2021.
Scholia has a profile for KD-414 (Q110269777). |
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|
This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |
Retrieved from "https://en.wikipedia.org/w/index.php?title=KD-414&oldid=1062046686"
Hidden categories:
- Articles with short description
- Short description matches Wikidata
- Use dmy dates from December 2021
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a vaccine
- All stub articles